RxDoctor Payments DataLook up a doctor →

Alexandra Borsboom

Adult Health · Magnolia, TXNPI 1568822435

Payments from drug & device makers

$8,779in general payments, 2019–2025

Across 453 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$976
  • AstraZeneca$907
  • Lilly USA, LLC$550
  • Amgen$355
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$1,20014%
  • Food & beverage$7,57986%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,779 in reported general payments places this provider in the 90th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$77,439
Medicare patients
127
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$77,425
JardianceEmpagliflozin48$58,678
OzempicSemaglutide36$52,769
Synjardy XrEmpagliflozin/Metformin Hcl23$33,866
TrulicityDulaglutide19$23,962
VraylarCariprazine Hcl18$23,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,403
FarxigaDapagliflozin Propanediol21$17,552
VascepaIcosapent Ethyl13$8,584
Frovatriptan Succinate16$3,273
Levothyroxine Sodium204$2,818
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,522
Celecoxib28$2,156
Metoprolol Succinate93$1,570
Rosuvastatin Calcium149$1,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$550$101,38880 claims
Boehringer IngelheimJardiance, Synjardy Xr$318$92,54471 claims
Novo NordiskOzempic$1,554$52,76936 claims
GSKTrelegy Ellipta, Shingrix$216$24,92536 claims
AbbVieVraylar$976$23,82818 claims
AstraZenecaFarxiga$907$17,55221 claims
Acella Pharmaceuticals, LLCNp Thyroid$17$55611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 adult health providers in Texas.

Other adult health in Magnolia

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →